TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18697469
Drug: 3-month depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-month depot (Zoladex LA 10.8 mg)
Study: 16032972
Drug: Commercially available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available preparation (reference)
Study: 7565948
Drug: cisapride (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: cisapride (10 mg three times a day)
Study: 7565948
Drug: ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidine (150 mg three times a day)
Study: 7565948
Drug: omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: omeprazole (20 mg per day)
Study: 7565948
Drug: ranitidine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidine plus cisapride (10 mg three times a day)
Study: 540455
Drug: metoprolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol (100 mg twice daily)
Study: 25831670
Drug: 5ml of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5ml of 2% lidocaine intrauterine (Group L)
Study: 25831670
Drug: 5ml of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5ml of 2% lidocaine intrauterine + 50mg of rectal diclofenac sodium (Group LD)
Study: 23885143
Drug: Active Dietary
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Dietary Intervention (ADI) - 175 mg milk thistle extract, 20 mg secoisolariciresinol, 750 mg oat fiber extract, administered twice a day for 60 days
Study: 21484280
Drug: Community-based STI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based STI treatment and counseling
Study: 19661116
Drug: Renal dysfunction
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renal dysfunction (eGFR <60 mL/min/1.73 m²)
Study: 19661116
Drug: Worsening renal
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Worsening renal function (decrease of eGFR of at least 15 mL/min/1.73 m² within 1 year)
Study: 17227997
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (750 mg/day), Vitamin E (600 mg/day), and Beta-carotene (18 mg/day)
Study: 12872340
Drug: Fulvestrant 250
Normalized name: fulvestrant 250 MG in 5 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulvestrant 250 mg monthly
Study: 10972174
Drug: Bovine immunoglobulin
Normalized name: Bovine immunoglobulin concentrate, cryptosporidium parvum
DrugBank: Cryptosporidium immune globulin (DB17785)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine immunoglobulin milk concentrate (BIC) 20 g daily for 4 days
Study: 8730344
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blockers (CCBs), n = 14
Study: 8730344
Drug: ACE inhibitors,
Normalized name: ACE INHIBITORS, PLAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors, n = 12
Study: 4054203
Drug: Nisoldipine, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine, 10 mg
Study: 4054203
Drug: Nifedipine, 20
Normalized name: Nifedipine, 20 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine, 20 mg retard
Study: 31728025
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy arm
Study: 31728025
Drug: Dose-dense treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-dense treatment arm
Study: 18626830
Drug: Early abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early abciximab administration before transfer to the catheterisation laboratory (27 patients)
Study: 18626830
Drug: Late abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Late abciximab administration in the catheterisation laboratory just before pPCI (32 patients)
Study: 15886988
Drug: Rigid gold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rigid gold implants
Study: 9806046
Drug: RTS,S malaria
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S malaria vaccine (vaccine 3)
Study: 23962071
Drug: RTS,S malaria
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S malaria vaccine
Study: 7644924
Drug: Paclitaxel (135-225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (135-225 mg/m2) and Carboplatin (250-400 mg/m2)
Study: 2654758
Drug: L-carnitine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine therapy (2 g twice daily for 45 weeks)
Study: 321198
Drug: Mesoridazine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesoridazine (10 mg tablets)
Study: 29577365
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg oleuropein
Study: 26758035
Drug: Craniosacral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Craniosacral therapy (IG)
Study: 24967345
Drug: NeReBot robotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: NeReBot robotic therapy
Study: 24967345
Drug: Conventional rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional rehabilitation therapy
Study: 22397784
Drug: Tadalafil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil (10 mg nightly) with standard treatment of BPH
Study: 22397784
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment of BPH (placebo group)
Study: 18063874
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B (L-AmB) prophylaxis
Study: 15240596
Drug: Individualized dosing
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized dosing regimen (ID) starting at 0.2 mg/d, increased by 0.2 mg/d increments to a maximum of 0.8 mg/d
Study: 15240596
Drug: Fixed body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed body weight-based dosing regimen (FD) with sequential doses of 4, 8, and 12 microg/kg.d GH
Study: 8317646
Drug: 10% lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% lignocaine gel with absorption promoter
Study: 357073
Drug: 5 consecutive
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 consecutive topical applications with APF gel (1.2% F, pH 3.2)
Study: 357073
Drug: 10 consecutive
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 consecutive topical applications with APF gel (1.2% F, pH 3.2)
Study: 357073
Drug: 25 consecutive
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 consecutive topical applications with APF gel (1.2% F, pH 3.2)
Study: 30668660
Drug: Buccal miniscrews
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal miniscrews
Study: 27541067
Drug: Auricular acupressure
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular acupressure therapy applied on acupoints (Jagung, Sinmun, Gyogam, Naebunbi) for 3 days during periods of extreme primary dysmenorrhea.
Study: 24656425
Drug: Artemether (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether (80 mg once per day during the second week and fourth week)
Study: 14609531
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical looking capsules)
Study: 19440077
Drug: OROS methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS methylphenidate (36, 54, 72, 90, or 108 mg/d)
Study: 11642642
Drug: Combined spa-exercise
Normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined spa-exercise therapy (3 weeks duration) including group physical exercises, walking, correction therapy, hydrotherapy, sports, and sauna visits.
Study: 11642642
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (usual drug treatment and weekly group physical therapy).
Study: 2492232
Drug: Depot leuprolide
Normalized name: leuprolide acetate Injectable Suspension [Lupron Depot]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depot leuprolide acetate (LA) 3.75 mg IM every 4 weeks for 24 weeks (Group A)
Study: 2492232
Drug: IM placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM placebo with the same injection schedule (Group B)
Study: 4338548
Drug: Simultaneous alpha
Normalized name: alpha tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous alpha and beta receptor blockade
Study: 27181910
Drug: Teneligliptin 5
Normalized name: teneligliptin
DrugBank: Teneligliptin (DB11950)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Teneligliptin 5 to 40 mg once daily for 24 weeks
Study: 27181910
Drug: Teneligliptin 20
Normalized name: teneligliptin
DrugBank: Teneligliptin (DB11950)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Teneligliptin 20 mg once daily during 28-week open label extension
Study: 24838155
Drug: Saxagliptin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saxagliptin (5 mg once daily)
Study: 20144258
Drug: Rooibos tea
Normalized name: SODIUM FLUORIDE 0.2 mg in 1 mL ORAL LIQUID [Hoo Gargle Rooibos Tea Flavor]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rooibos tea (400 ml)
Study: 20144258
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea (400 ml)
Study: 1732429
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of high-dose recombinant interleukin-2 (rIL-2) three times daily
Study: 1732429
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of high-dose recombinant interleukin-2 (rIL-2) 24-hour infusion
Study: 6396239
Drug: Hydrochlorothiazide-amiloride combination
Normalized name: amiloride / hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide-amiloride combination
Study: 12001821
Drug: Tolterodine 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine 5 mg
Study: 28300854
Drug: Oxybutynin 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin 7.5 mg
Study: 7795832
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of weight loss and sodium restriction
Study: 1737537
Drug: Topical 0.075%
Normalized name: capsaicin topical 0.075% topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.075% capsaicin cream
Study: 24577921
Drug: Ocucure (Test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocucure (Test drug) 500mg, two tablets twice daily for 6-8 weeks
Study: 24577921
Drug: Leutivit (Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leutivit (Control drug) 250mg, two tablets twice daily for 6-8 weeks
Study: 24577921
Drug: Ocucure (Test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocucure (Test drug)
Study: 9695216
Drug: Oral cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclophosphamide (1.5-2.0 mg/kg/day for 6 months)
Study: 9695216
Drug: Intravenous cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclophosphamide pulses (20 mg/kg/monthly for at least 6 pulses) combined with oral prednisolone (40-60 mg/day for 1.5 months with tapering)
Study: 30063470
Drug: Intravenous cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclophosphamide pulses
Study: 1864449
Drug: 4% indomethacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% indomethacin spray
Study: 26915677
Drug: Idelalisib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idelalisib (100 mg twice daily)
Study: 15863638
Drug: Nasal continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal continuous positive airway pressure treatment
Study: 30156211
Drug: Periarticular multimodal
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periarticular multimodal drug injection (200 mg ropivacaine, 30 mg ketorolac tromethamine, 0.3 mg epinephrine, 5 mg hexadecadrol)
Study: 26857465
Drug: 15 mL
Normalized name: ethanol 0.15 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mL water swallow
Study: 25381136
Drug: Eribulin (1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eribulin (1.4 mg/m2 on days 1 and 8 every 21 days)
Study: 25381136
Drug: Control (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (treatment of physician’s choice or capecitabine 1.25 g/m2 b.i.d. on days 1–14 every 21 days)
Study: 10228288
Drug: Short course
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short course indomethacin (0.2 to 0.1 to 0.1 mg/kg in 24 hours, n = 31)
Study: 10228288
Drug: Long course
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long course indomethacin (0.1 mg/kg every 24 hours for 7 times, n = 30)
Study: 1321893
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy and radiotherapy (RT) including cisplatin 100 mg/m2 on days 1 and 29, vinblastine 3 mg/m2 on days 1, 3, 29, and 31, fluorouracil (5-FU) 30 mg/kg/d by infusion on days 1 to 3 and 29 to 31, and RT of 3,000 cGy in 15 fractions.
Study: 1321893
Drug: Surgical resection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical resection following neoadjuvant treatment.
Study: 1321893
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy and RT followed by additional chemotherapy and RT after surgery.
Study: 21038652
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with BG, BP, BL controlling and vitamin E administration (Group C)
Study: 21038652
Drug: Group with
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group with BG, BP, BL controlling and DSP administration (Group D)
Study: 17992056
Drug: Acupuncture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture therapy and physical therapy
Study: 799986
Drug: Tofranil 25
Normalized name: Tofranil 25mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofranil 25 mg three times daily
Study: 30284349
Drug: Oral semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral semaglutide (up to 14 mg)
Study: 20923251
Drug: DHEP/heparin plaster
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEP/heparin plaster
Study: 15941146
Drug: Nebivolol (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol (1.25 to 5 mg per day)
Study: 15941146
Drug: Betalok ZOK
Normalized name: Zokinvy
DrugBank: Lonafarnib (DB06448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betalok ZOK (12.5 to 100 mg per day)
Study: 12817904
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg lithium
Study: 22262484
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline infusion
Study: 6812750
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline 9 g/l)
Study: 30118528
Drug: Platform-switching implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platform-switching implant (PS)
Study: 30118528
Drug: Platform-switching implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platform-switching implant and bone graft (BG/PS)
Study: 30118528
Drug: Non-platform-switching implant
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-platform-switching implant (Non-PS)
Study: 30118528
Drug: Non-platform-switching implant
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-platform-switching implant and bone graft (BG/Non-PS)
Study: 30118528
Drug: Platform-switching implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platform-switching implant (PS) and bone graft (BG/PS)
Study: 27614801
Drug: 4 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g/d omega-3 fatty acid supplementation
Study: 17418112
Drug: Familiar solution
Normalized name: Canis lupus familiaris skin
DrugBank: Canis lupus familiaris skin (DB10409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Familiar solution (non-optimal solution)
Study: 15866569
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (600 microg of busereline acetate per day starting in the midluteal phase of the cycle)
Study: 15866569
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist (0.25 mg/d of Cetrorelix starting from day 6 of the cycle)
Study: 18411913
Drug: Transdermal hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal hormone replacement therapy (HRT)
Study: 1907128
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment (NO RT)
Study: 30157532
Drug: Liraglutide (≤1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (≤1.8 mg daily)
Study: 26429360
Drug: High-dose dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexmedetomidine (loading dose, 1 μg/kg; maintenance dose, 0.6 μg/kg/h)
Study: 26429360
Drug: Low-dose dexmedetomidine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dexmedetomidine (loading dose, 0.6 μg/kg; maintenance dose, 0.3 μg/kg/h)
Study: 26429360
Drug: High-dose dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexmedetomidine
Study: 12744870
Drug: CF‐BS‐ETEC vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: CF‐BS‐ETEC vaccine
Study: 7755164
Drug: β-lactam/β-lactamase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-lactam/β-lactamase inhibitor agents (ampicillin/sulbactam, ticarcillin/clavulanate, piperacillin/tazobactam)
Study: 7755164
Drug: aminoglycoside plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: aminoglycoside plus antianaerobic therapy
Study: 3031574
Drug: RIT 4237
Normalized name: measles virus vaccine live, attenuated Schwarz strain / mumps virus vaccine live, RIT-4385 strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection [Priorix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIT 4237 bovine rotavirus vaccine
Study: 29187694
Drug: 4 mg/day
Normalized name: Neupro 4 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/day pitavastatin
Study: 7987882
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day pravastatin
Study: 27264413
Drug: 30 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/day fluvastatin
Study: 19442931
Drug: Indomethacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (100 mg, oral, 90 min)
Study: 14693528
Drug: GW433908 1,395
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW433908 1,395 mg BID
Study: 14693528
Drug: GW433908 1,860
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW433908 1,860 mg BID
Study: 14693528
Drug: Amprenavir 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amprenavir 1,200 mg BID
Study: 9835204
Drug: Collagenase treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagenase treatment of aorta
Study: 2553325
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic factor infusion
Study: 15358983
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg L-dopa
Study: 2824706
Drug: Cisplatin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (200 mg/m2 divided in five daily doses) and vinblastine (7.5 mg/m2 as a continuous IV infusion over five days) followed by radiation therapy
Study: 2824706
Drug: Cisplatin and
Normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin and vinblastine followed by radiation therapy
Study: 2824706
Drug: Cisplatin and
Normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin and vinblastine followed by radiation therapy for nonresponders
Study: 30990213
Drug: Bread fortified
Normalized name: Eazi-Breed CIDR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bread fortified with 2.3 g PS and 228 mg CC (PS-C)
Study: 30990213
Drug: Bread fortified
Normalized name: Eazi-Breed CIDR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bread fortified with placebo (PL) and curcumin (CC) (PL-C)
Study: 26867333
Drug: Fennel tea
Normalized name: Fennel
DrugBank: Fennel (DB15615)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fennel tea (5 grams of dried fennel fruit in 130 mL boiled water, twice per day)
Study: 26867333
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (equal quantity of water, twice per day)
Study: 21710343
Drug: High-dose N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose N-acetylcysteine (N-ACC) 2 × 1200 mg/d for 48 h with optimal hydration
Study: 16524858
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no LT4 therapy)
Study: 15631797
Drug: Cefdinir 100
Normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefdinir 100 mg, orally, three times a day for 7-14 days
Study: 15631797
Drug: Cefaclor 500
Normalized name: cefaclor 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor 500 mg, orally, three times a day for 7-14 days
Study: 9379067
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia (PCA) with background opioid infusion
Study: 2863392
Drug: 10 mg.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg. dezocine
Study: 2863392
Drug: 15 mg.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg. dezocine
Study: 2863392
Drug: 10 mg.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg. morphine